Guy Bower1, Tania Toma1, Leanne Harling1, Long R Jiao1,2, Evangelos Efthimiou1,3, Ara Darzi1, Thanos Athanasiou1, Hutan Ashrafian4,5,6. 1. Department of Surgery and Cancer, Imperial College London, London, UK. 2. Department of Hepatobiliary and Pancreatic Surgery, Imperial College Healthcare NHS Trust, London, UK. 3. Department of Bariatric Surgery, Chelsea and Westminster Hospital, London, UK. 4. Department of Surgery and Cancer, Imperial College London, London, UK. h.ashrafian@imperial.ac.uk. 5. Department of Bariatric Surgery, Chelsea and Westminster Hospital, London, UK. h.ashrafian@imperial.ac.uk. 6. Department of Hepatobiliary and Pancreatic Surgery, Imperial College Healthcare NHS Trust, London, UK. h.ashrafian@imperial.ac.uk.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is becoming a leading cause of global liver disease that is associated with the rising prevalence of obesity worldwide. There is now increasing clinical and mechanistic evidence reporting on the metabolic and weight loss effects of bariatric surgery on improving NAFLD in obese patients. OBJECTIVES: The aim of this paper was to quantify the effects of bariatric surgery on NAFLD by appraising the modulation between pre- and post-operative liver enzyme levels (as markers of liver injury) and liver histology. METHODS: A systematic review of studies reporting pre-operative and post-operative liver enzymes or liver histology was done in obese patients with NAFLD undergoing bariatric surgery. Data were meta-analysed using random-effects modelling. Subgroup analysis, quality scoring and risk of bias were assessed. RESULTS: Bariatric surgery is associated with a significant reduction in the weighted incidence of a number of histological features of NAFLD including steatosis (50.2 and 95 %CI of 35.5-65.0), fibrosis (11.9 and 95 %CI of 7.4-16.3 %), hepatocyte ballooning (67.7 and 95 %CI 56.9-78.5) and lobular inflammation (50.7 and 95 %CI 26.6-74.8 %). Surgery is also associated with a reduction in liver enzyme levels, with statistically significant reductions in ALT (11.36 u/l, 95 %CI 8.36-14.39), AST (3.91 u/l, 95 %CI 2.23-5.59), ALP (10.55 u/l, 95 %CI 4.40-16.70) and gamma-GT (18.39 u/l, 95 %CI 12.62-24.16). Heterogeneity in results was high. CONCLUSIONS: Bariatric surgery is associated with a significant improvement in both histological and biochemical markers of NAFLD. Future studies must focus on higher levels of evidence to better identify the benefits of bariatric surgery on liver disease in order to enhance future treatment strategies in the management of NAFLD.
BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is becoming a leading cause of global liver disease that is associated with the rising prevalence of obesity worldwide. There is now increasing clinical and mechanistic evidence reporting on the metabolic and weight loss effects of bariatric surgery on improving NAFLD in obesepatients. OBJECTIVES: The aim of this paper was to quantify the effects of bariatric surgery on NAFLD by appraising the modulation between pre- and post-operative liver enzyme levels (as markers of liver injury) and liver histology. METHODS: A systematic review of studies reporting pre-operative and post-operative liver enzymes or liver histology was done in obesepatients with NAFLD undergoing bariatric surgery. Data were meta-analysed using random-effects modelling. Subgroup analysis, quality scoring and risk of bias were assessed. RESULTS: Bariatric surgery is associated with a significant reduction in the weighted incidence of a number of histological features of NAFLD including steatosis (50.2 and 95 %CI of 35.5-65.0), fibrosis (11.9 and 95 %CI of 7.4-16.3 %), hepatocyte ballooning (67.7 and 95 %CI 56.9-78.5) and lobular inflammation (50.7 and 95 %CI 26.6-74.8 %). Surgery is also associated with a reduction in liver enzyme levels, with statistically significant reductions in ALT (11.36 u/l, 95 %CI 8.36-14.39), AST (3.91 u/l, 95 %CI 2.23-5.59), ALP (10.55 u/l, 95 %CI 4.40-16.70) and gamma-GT (18.39 u/l, 95 %CI 12.62-24.16). Heterogeneity in results was high. CONCLUSIONS: Bariatric surgery is associated with a significant improvement in both histological and biochemical markers of NAFLD. Future studies must focus on higher levels of evidence to better identify the benefits of bariatric surgery on liver disease in order to enhance future treatment strategies in the management of NAFLD.
Entities:
Keywords:
Bariatric surgery; Body mass index; Intervention; Metabolic surgery; NAFLD; Non-alcoholic fatty liver disease; Surgery; Weight loss
Authors: Kevin B Barker; Nicole A Palekar; Steven P Bowers; Joel E Goldberg; Joseph P Pulcini; Stephen A Harrison Journal: Am J Gastroenterol Date: 2006-02 Impact factor: 10.864
Authors: Steve C N Hui; Simon K H Wong; Qiyong Ai; David K W Yeung; Enders K W Ng; Winnie C W Chu Journal: Eur Radiol Date: 2018-07-30 Impact factor: 5.315
Authors: Maurizio De Luca; Luigi Angrisani; Jacques Himpens; Luca Busetto; Nicola Scopinaro; Rudolf Weiner; Alberto Sartori; Christine Stier; Muffazal Lakdawala; Aparna G Bhasker; Henry Buchwald; John Dixon; Sonja Chiappetta; Hans-Christian Kolberg; Gema Frühbeck; David B Sarwer; Michel Suter; Emanuele Soricelli; Mattias Blüher; Ramon Vilallonga; Arya Sharma; Scott Shikora Journal: Obes Surg Date: 2016-08 Impact factor: 4.129
Authors: S Sherf-Dagan; S Zelber-Sagi; G Zilberman-Schapira; M Webb; A Buch; A Keidar; A Raziel; N Sakran; D Goitein; N Goldenberg; J A Mahdi; M Pevsner-Fischer; N Zmora; M Dori-Bachash; E Segal; E Elinav; O Shibolet Journal: Int J Obes (Lond) Date: 2017-08-30 Impact factor: 5.095